Vivos Therapeutics Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
VVOS Nasdaq 3841 https://vivos.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vivos Therapeutics Inc

Vivos Therapeutics talks clinical study success of POD migraine treatment, new timeline for cashflow - May 16th, 2023 5:19 pm
Vivos Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations - May 9th, 2023 11:30 am
A Headache-Free Future? Vivos' POD Device Slashes Migraine Symptoms by 89% in Clinical Study - May 1st, 2023 8:09 pm
Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ POD® Appliance Treatment - May 1st, 2023 11:30 am
The Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analyst Just Cut Their Revenue Forecast By 14% - Apr 5th, 2023 10:36 am
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2022 Earnings Call Transcript - Apr 4th, 2023 4:30 pm
Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update - Mar 30th, 2023 8:05 pm
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call - Mar 30th, 2023 11:30 am
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference - Mar 8th, 2023 12:30 pm
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC - Mar 1st, 2023 12:30 pm
Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Feb 21st, 2023 9:05 pm
Presenting on the Emerging Growth Conference on February 22 Register Now - Feb 21st, 2023 12:00 pm
7 Micro-Cap Stocks to Buy for Risk-Taking Investors - Jan 27th, 2023 12:05 pm
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements - Jan 20th, 2023 12:30 pm
Vivos Therapeutics Closes $8 Million Private Placement - Jan 9th, 2023 9:45 pm
Vivos Therapeutics Announces Pricing of $8 Million Private Placement - Jan 5th, 2023 1:10 pm
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea - Jan 4th, 2023 12:30 pm
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update - Dec 20th, 2022 9:15 pm
Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call - Dec 16th, 2022 12:30 pm
Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems - Dec 15th, 2022 12:30 pm